{"id":23912,"date":"2024-04-22T11:27:56","date_gmt":"2024-04-22T09:27:56","guid":{"rendered":"https:\/\/ggba.swiss\/?p=23912"},"modified":"2024-04-22T11:27:57","modified_gmt":"2024-04-22T09:27:57","slug":"isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/","title":{"rendered":"Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding"},"content":{"rendered":"\n

Isospec<\/a> focuses on analyzing small molecules in blood, offering rapid and profound insights into human health, with the potential to significantly improve disease diagnosis and treatment. Currently operating from a lab, the company has already begun offering molecular identification services commercially, with clients across Europe, the US, and Japan. This capability is critical, as traditional methods can take weeks or months to identify a fraction of the molecules that Isospec’s technology can detect in hours. This swift identification process is thanks to the integration of advanced fields such as analytical chemistry, photonics, and cryogenics.<\/p>\n\n\n\n

The Vaud-based company\u2019s groundbreaking approach not only speeds up the identification process but also enhances understanding of diseases by detecting biomarkers in blood that indicate health issues, such as lung cancer, at their onset. This early detection is vital for timely and effective treatment.<\/p>\n\n\n\n

Moreover, Isospec\u2019s collaborations with hospitals and research institutes are crucial as they work together to understand the significance of these biomarkers in clinical settings. The aim is to develop diagnostic tests that can provide rapid and accurate health assessments, thereby improving patient outcomes.<\/p>\n\n\n\n

With plans to use its recent funding to invest in automation technologies and software engineering, Isospec is enhancing its testing capabilities and operational efficiency. The USD 1.9 million funding will support the company’s growth and help expedite the commercialization of its diagnostic services.<\/p>\n\n\n\n

Isospec’s potential extends beyond diagnostics, as the insights gained from its technology could lead to new drug developments and treatments. The investment from Founderful<\/a> and other partners highlights strong confidence in Isospec’s innovative diagnostic technology, which promises to transform medical diagnostics and treatment approaches. This advancement could dramatically enhance patient care and quality of life globally.<\/p>\n","protected":false},"excerpt":{"rendered":"

Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding to advance its revolutionary diagnostic technologies.<\/p>\n","protected":false},"author":6,"featured_media":23913,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,908,894,902,911],"class_list":["post-23912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-diagnostic","tag-financing","tag-personalized-medicine","tag-pharma"],"acf":[],"yoast_head":"\nIsospec pioneers diagnostic technologies with USD 1.9M funding<\/title>\n<meta name=\"description\" content=\"Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Isospec pioneers diagnostic technologies with USD 1.9M funding\" \/>\n<meta property=\"og:description\" content=\"Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-22T09:27:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-22T09:27:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1179\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding\",\"datePublished\":\"2024-04-22T09:27:56+00:00\",\"dateModified\":\"2024-04-22T09:27:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\"},\"wordCount\":294,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Diagnostic\",\"Financing\",\"Personalized Medicine\",\"Pharma\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\",\"url\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\",\"name\":\"Isospec pioneers diagnostic technologies with USD 1.9M funding\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg\",\"datePublished\":\"2024-04-22T09:27:56+00:00\",\"dateModified\":\"2024-04-22T09:27:57+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg\",\"width\":1179,\"height\":811,\"caption\":\"Founded by EPFL alumni Thomas Rizzo, Ahmed Ben Faleh and Stephan Warnke, Isospec is set to transform health diagnostics with its unique ability to identify a vast array of molecules from human blood samples rapidly. | \u00a9 Isospec\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Isospec pioneers diagnostic technologies with USD 1.9M funding","description":"Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/","og_locale":"en_US","og_type":"article","og_title":"Isospec pioneers diagnostic technologies with USD 1.9M funding","og_description":"Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding.","og_url":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-04-22T09:27:56+00:00","article_modified_time":"2024-04-22T09:27:57+00:00","og_image":[{"width":1179,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding","datePublished":"2024-04-22T09:27:56+00:00","dateModified":"2024-04-22T09:27:57+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/"},"wordCount":294,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg","keywords":["Biotech","Diagnostic","Financing","Personalized Medicine","Pharma"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/","url":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/","name":"Isospec pioneers diagnostic technologies with USD 1.9M funding","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg","datePublished":"2024-04-22T09:27:56+00:00","dateModified":"2024-04-22T09:27:57+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Isospec-1180x811-1.jpg","width":1179,"height":811,"caption":"Founded by EPFL alumni Thomas Rizzo, Ahmed Ben Faleh and Stephan Warnke, Isospec is set to transform health diagnostics with its unique ability to identify a vast array of molecules from human blood samples rapidly. | \u00a9 Isospec"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/isospec-pioneers-rapid-diagnostic-technologies-with-usd-1-9-million-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/23912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=23912"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/23912\/revisions"}],"predecessor-version":[{"id":23916,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/23912\/revisions\/23916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/23913"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=23912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=23912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=23912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}